ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Hot Features

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
Entrar Premium IconPremium Help Menu
Índice Bovespa
119.878,07
-1,44%
S&P 500
5.414,82
0,73%
US Dollar vs BRL
5,38984
0,44%
Bitcoin
68.497,55
1,74%
Brent Oil
82,135
0,16%
Registration Strip Icon for smarter Negocie de forma mais inteligente, não mais difícil: Libere seu potencial com nosso conjunto de ferramentas e discussões ao vivo.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Travere Therapeutics Inc (TVTX)

  7. Travere Therapeutics Inc (TVTX) Notícias

TVTX

Travere Therapeutics (TVTX)

Travere Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:TVTX
DataHoraFonteTítuloCódigoCompanhia
11/06/202418:00GlobeNewswire Inc.Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:TVTXTravere Therapeutics Inc
13/05/202417:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TVTXTravere Therapeutics Inc
10/05/202417:06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TVTXTravere Therapeutics Inc
09/05/202417:30GlobeNewswire Inc.Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association CongressNASDAQ:TVTXTravere Therapeutics Inc
08/05/202417:30GlobeNewswire Inc.Travere Therapeutics to Present at Upcoming Investor ConferencesNASDAQ:TVTXTravere Therapeutics Inc
06/05/202417:46Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TVTXTravere Therapeutics Inc
06/05/202417:01GlobeNewswire Inc.Travere Therapeutics Reports First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
29/04/202417:30GlobeNewswire Inc.Travere Therapeutics to Report First Quarter 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
24/04/202408:05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
24/04/202404:00PR Newswire (US)CSL Vifor and Travere Therapeutics Announce European Commission approves FILSPARI® (sparsentan) for the treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
04/04/202417:30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians InternationalNASDAQ:TVTXTravere Therapeutics Inc
03/04/202417:30GlobeNewswire Inc.Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses AssociationNASDAQ:TVTXTravere Therapeutics Inc
11/03/202408:05GlobeNewswire Inc.Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)NASDAQ:TVTXTravere Therapeutics Inc
23/02/202409:05GlobeNewswire Inc.Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA NephropathyNASDAQ:TVTXTravere Therapeutics Inc
23/02/202404:00PR Newswire (Canada)CSL Vifor and Travere Therapeutics announce sparsentan receives positive CHMP opinion for the treatment of IgA nephropathyNASDAQ:TVTXTravere Therapeutics Inc
20/02/202410:10Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TVTXTravere Therapeutics Inc
15/02/202418:01GlobeNewswire Inc.Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
14/02/202416:35Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:TVTXTravere Therapeutics Inc
08/02/202418:30GlobeNewswire Inc.Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
01/02/202423:58Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:TVTXTravere Therapeutics Inc
01/02/202418:30GlobeNewswire Inc.Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology ConferenceNASDAQ:TVTXTravere Therapeutics Inc
25/01/202418:05GlobeNewswire Inc.Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian NationsNASDAQ:TVTXTravere Therapeutics Inc
08/01/202409:00GlobeNewswire Inc.Travere Therapeutics Provides Corporate Update and 2024 OutlookNASDAQ:TVTXTravere Therapeutics Inc
02/01/202418:30GlobeNewswire Inc.Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:TVTXTravere Therapeutics Inc
14/12/202309:30GlobeNewswire Inc.Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)NASDAQ:TVTXTravere Therapeutics Inc
04/12/202319:14Dow Jones NewsTravere Shares Rise 8.4%; Co. To Cut Staff, Focus on IgAN, HCU TreatmentsNASDAQ:TVTXTravere Therapeutics Inc
04/12/202318:05GlobeNewswire Inc.Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGSNASDAQ:TVTXTravere Therapeutics Inc
21/11/202318:30GlobeNewswire Inc.Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx ConferenceNASDAQ:TVTXTravere Therapeutics Inc
07/11/202318:01GlobeNewswire Inc.Travere Therapeutics Reports Third Quarter 2023 Financial ResultsNASDAQ:TVTXTravere Therapeutics Inc
03/11/202311:46GlobeNewswire Inc.Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023NASDAQ:TVTXTravere Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:TVTX

Seu Histórico Recente

COIN
FAOETH
FarmerAndOne Token
LSE
FUSR
Fid Sre Us Etf
AMEX
URX
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2024 ADVFN PLC - Todos os direitos reservados